LivaNova PLC: Neuromodulation Publishes Full 36-Month CORE-VNS Results Demonstrating Sustained and Increasing Benefits of LivaNova's VNS Therapy for Drug-Resistant Epilepsy
LivaNova PLC (LIVN) reported 36-month results from the CORE-VNS study, showing a 76% median reduction in seizure frequency for drug-resistant epilepsy patients using its VNS Therapy. The study also found improvements in quality of life, healthcare resource utilization, and seizure severity. The data was published in the journal Neuromodulation.
How this was made
The 30-second read
Why it matters
The 36‑month results provide the most comprehensive efficacy evidence to date, likely improving analyst outlooks and supporting future revenue growth from device sales and related services.
Market read
First‑time disclosure of robust long‑term VNS efficacy, a material catalyst for LIVN and the neuromodulation sector.
What to watch
Potential regulatory hurdles in key markets and competition from emerging non‑invasive neuro‑stimulation modalities.
Background
LivaNova (NASDAQ:LIVN) is a leading medical‑technology company focused on neuromodulation devices. The CORE‑VNS study is a multinational, prospective observational trial of its VNS Therapy for drug‑resistant epilepsy.
Ticker impact
LivaNova announced full 36‑month CORE‑VNS study results showing 76% median seizure reduction and improved quality of life, the first long‑term efficacy data for its VNS Therapy.
potential upside as investors price in stronger product efficacy and future sales growth
The study provides new, material evidence of product effectiveness, a key driver for med‑tech revenue forecasts.
Market effects
Strengthens the neuromodulation/medical‑device sector by validating VNS therapy, may boost peers with similar technologies.
Positive for US‑listed med‑tech stocks; limited immediate effect on broader markets.
Highlights growing importance of neuro‑stimulation therapies worldwide.
Counterpoint
Skeptics may question long‑term adoption rates and reimbursement, suggesting the data may not translate into immediate sales.
Key entities
- CompanyLivaNova PLC
Medical‑technology firm developing VNS Therapy.
- JournalNeuromodulation: Technology at the Neural Interface
Publication that released the study findings.
